Testagen vs Syn-Coll
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
- Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Extended (lipid depot in stratum corneum)
- Admin Route
- SubQ, Oral
- Topical
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.005-0.05% in formulation
- Frequency
- Daily for 10–30 days
- Once or twice daily
- Key Benefits
- Supports endogenous testosterone synthesis via Leydig cell normalization
- Promotes spermatogenesis and sperm quality
- Anti-aging effects on testicular tissue
- May attenuate age-related testosterone decline
- Mechanistically distinct from TRT — does not suppress HPG axis
- Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
- Supports male fertility without exogenous hormone replacement
- Directly activates TGF-beta for potent collagen synthesis stimulation
- Increases dermal thickness and firmness
- Reduces depth of wrinkles and fine lines
- Improves skin elasticity
- Clinically validated in collagen induction studies
- Complementary to retinoids or vitamin C
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant endocrine disruption reported at standard doses
- Generally well-tolerated
- Rare mild irritation at high concentrations
- Possible sensitivity in individuals with inflammatory skin conditions
- Stacks With
- —
- —